Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Viral Recombination

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Vaccinations

Vaccinations

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

COX-2 inhibition improves immune system homeostasis and decreases liver damage in septic rats.

The Journal of surgical research·2009

Same author

Mass spectral characterization of organophosphate-labeled, tyrosine-containing peptides: characteristic mass fragments and a new binding motif for organophosphates.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2009

Same author

3D-SURFER: software for high-throughput protein surface comparison and analysis.

Bioinformatics (Oxford, England)·2009

Same author

Total arch replacement with stented elephant trunk technique: a proposed treatment for complicated Stanford type B aortic dissection.

Journal of cardiac surgery·2009

Same author

Top-emitting white organic light-emitting devices with a one-dimensional metallic-dielectric photonic crystal anode.

Optics letters·2009

Same author

[Detection of tick and tick-borne pathogen in some ports of Inner Mongolia].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2009

Search research articles

Related Experiment Video

Updated: May 30, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumococcal vaccines in China.

Shanshan Wang¹, Bin Li¹, Qiong Chen¹

¹Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes of Food and Drug Control, Beijing, People's Republic of China.

Human Vaccines & Immunotherapeutics

|January 30, 2025

Summary

Invasive pneumococcal disease (IPD) poses a significant threat in China. This review examines IPD, available vaccines like PPV23 and PCV13, and strategies for better control and monitoring.

Keywords:

China Streptococcus pneumoniae conjugate vaccine pneumonia disease polysaccharide vaccine quality control

More Related Videos

Experimental Human Pneumococcal Carriage

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Experiment Videos

Last Updated: May 30, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Experimental Human Pneumococcal Carriage

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Area of Science:

Public Health
Vaccinology
Microbiology

Background:

Invasive pneumococcal disease (IPD) is a major cause of illness and death in China.
Pneumococcal vaccines are crucial for preventing IPD, with PPV23 and PCV13 available domestically.

Purpose of the Study:

To review the current landscape of IPD in China.
To assess the status of pneumococcal vaccines and their quality control.
To identify challenges and future directions for IPD control.

Main Methods:

Literature review of IPD epidemiology.
Analysis of available pneumococcal vaccine data in China.
Discussion of quality control measures and disease burden.

Main Results:

IPD remains a significant public health concern in China.
Domestic production of PPV23 and PCV13 vaccines is established.
Potential for IPD caused by non-vaccine serotypes requires consideration.

Conclusions:

Effective IPD control requires ongoing evaluation of disease burden.
Monitoring vaccine effectiveness is essential for public health strategies.
Addressing challenges in vaccination and quality control is critical for reducing IPD.